Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01416337 · ClinicalTrials.gov registry record · Phase 1
Absolute Bioavialability of GSK1120212
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01416337: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT01416337 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01416337, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
A Phase I, single-center, open-label, single-persiod, combined single dose oral and IV microtracer study in subjects with solid tumors.
Primary Outcome
Absolute bioavailability (F) of GSK1120212 calculated as the ratio of dose-normalized area under the concentration-time curve from time 0 (pre-dose) extrapolated to infinity (AUC(0-inf)) of oral to IV dosing
Interventions
- DRUG GSK1120212
- DRUG GSK1120212B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-06-20 |
| Est. Completion | 2011-12-17 |
| Phase | Phase 1 |
What the finished NCT01416337 record still lists
NCT01416337 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which GSK1120212 is the first listed.
NCT01416337 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01416337 about?
NCT01416337 is a clinical study titled "Absolute Bioavialability of GSK1120212". A Phase I, single-center, open-label, single-persiod, combined single dose oral and IV microtracer study in subjects with solid tumors.
What is the current status of trial NCT01416337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-06-20. Estimated completion is 2011-12-17.
What interventions are being tested in trial NCT01416337?
The interventions under investigation include: GSK1120212 (DRUG), GSK1120212B (DRUG).
Who is sponsoring clinical trial NCT01416337?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01416337's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI